Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 6/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | HTT | P42858 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.46 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.46 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.46 |
| ▸ | CDC25B | P30305 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 6/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.38 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4440995 | 0.84 | BCL2 (0.43) | MAPK1ALDH1A1HTTNPC1RAB9A | |
| SCHEMBL7416176 | 0.84 | BCL2 (0.43) | MAPK1ALDH1A1HTTNPC1RAB9A | |
| SCHEMBL7412611 | 0.84 | HCAR3 (0.41) | HCAR3MAPK1ALDH1A1HTTNPC1 | |
| SCHEMBL4443935 | 0.84 | HCAR3 (0.41) | HCAR3MAPK1ALDH1A1HTTNPC1 | |
| SCHEMBL7417312 | 0.82 | HCAR3 (0.44) | HCAR3MAPK1ALDH1A1HTTNPC1 | |
| SCHEMBL27508286 | 0.77 | ALDH1A1 (0.48) | HCAR3MAPK1ALDH1A1HTTNPC1 | |
| SCHEMBL27508285 | 0.77 | ALDH1A1 (0.48) | HCAR3MAPK1ALDH1A1HTTNPC1 | |
| SCHEMBL30573735 | 0.76 | ALDH1A1 (0.64) | HCAR3MAPK1ALDH1A1HTTNPC1 | |
| SCHEMBL3369544 | 0.74 | KCNMA1 (0.57) | MAPK1ALDH1A1HTTNPC1RAB9A | |
| SCHEMBL3946429 | 0.74 | GAA (0.44) | ALDH1A1NPC1RAB9AMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090022686-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF SYSTEMIC INFLAMMATORY RESPONSE SYNDROME | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-01-22 | — | — | US | disclosed |
| EP-1517687-B1 | MEDICAMENT FOR THE TREATMENT OF THE SYSTEMIC INFLAMMATORY RESPONSE SYNDROME | BOEHRINGER INGELHEIM PHARMA (DE) | 2007-06-20 | — | — | EP | disclosed |
| EP-1517687-A1 | MEDICAMENT FOR THE TREATMENT OF THE SYSTEMIC INFLAMMATORY RESPONSE SYNDROME | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-03-30 | — | — | EP | disclosed |
| US-20040023975-A1 | Pharmaceutical compositions for the treatment of systemic inflammatory response syndrome | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-02-05 | — | — | US | disclosed |
| WO-2004000310-A1 | MEDICAMENT FOR THE TREATMENT OF THE SYSTEMIC INFLAMMATORY RESPONSE SYNDROME | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-12-31 | — | — | WO | disclosed |
| US-6593355-B2 | 2-phenylaminomethyl benzimidazole derivatives | BOEHRINGER INGELEHIM PHARMA KG (DE) | 2003-07-15 | — | — | US | disclosed |
| US-20030004356-A1 | Benzimidazoles with antithrombotic activity | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-01-02 | — | — | US | disclosed |
| EP-1095025-B1 | BENZIMIDAZOLES, PRODUCTION THEREOF AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA (DE) | 2002-12-11 | — | — | EP | disclosed |
| US-6451832-B2 | E.G., 2-(AMINDINOPHENYLAMINOMETHYL)-1-METHYL-5-(1-(ETHOXY-CARBONYL-METHYLAMINO)-1 -(2,5-DIHYDROPYRROLOCARBONYL)-ETHYL)BENZIMIDAZOLE; ANTICOAGULANTS AND ANTITHROMBOLYTIC AGENTS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-09-17 | — | — | US | disclosed |
| US-20010006977-A1 | Benzimidazoles with antithrombotic activity | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2001-07-05 | — | — | US | disclosed |
| US-6248770-B1 | CARDIOVASCULAR DISORDERS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2001-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040023975-A1 | Pharmaceutical compositions for the treatment of systemic inflammatory response syndrome | IL5, TSLP, TLR5 | HCAR3 391/4885MAPK1 3070/4885ALDH1A1 1668/4885 |
| US-20090022686-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF SYSTEMIC INFLAMMATORY RESPONSE SYNDROME | IL5, TSLP, TLR5 | HCAR3 391/4885MAPK1 3070/4885ALDH1A1 1668/4885 |
| US-20030004356-A1 | Benzimidazoles with antithrombotic activity | SERPINC1, SERPINB1, PF4 | HCAR3 3521/4885MAPK1 3089/4885ALDH1A1 232/4885 |
| US-20010006977-A1 | Benzimidazoles with antithrombotic activity | SERPINC1, SERPINB1, PF4 | HCAR3 3521/4885MAPK1 3089/4885ALDH1A1 232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.